Support in USA : 1-978- 707-9553 / Support in India : +91- 9987711567

  • Apple Pharmaceuticals

Velasof - 12 weeks

HepatitisC-Hetero-Velpatasvir-100mg-Sofosbuvir-400mg-Velasof

Availability: In stock

Special Price $ 799

BRAND : Velasof
STRENGTH : 400 mg & 100 mg
INGREDIENT : HepatitisC-Hetero-Velpatasvir-100mg-Sofosbuvir-400mg-Velasof
COMPANY NAME : Hetero
COUNT : 28 Tablets



Description of Velasof - 12 weeks

Velasof – 12 weeks treatment Brand name: Velasof Active component: Sofosbuvir and Velpatasvir Strength of the components: 400mg and 100mg respectively Mfg: Hetero healthcare Package: 28 tablets in a container Velasof is a fixed dose combination drug, contains Sofosbuvir and Velpatasvir as a active ingredients. Both the components exhibit anti-viral activity. Velasof is a prescription medicine; it is taken by the patients only under the guidance of medical practitioner Velasof tablet is active against virus which causes hepatitis C infection in adults Velasof contains; Sofosbuvir-HCV NS5B polymerase inhibitor Velpatasvir-HCV NS5A inhibitor

Pharmacology of Velasof - 12 weeks

Mechanism of action: 12 weeks Velasof – Treatment for chronic hepatitis C viral infection for 12 weeks Sofosbuvir is one of the component of Velasof tablet, is an HCV NS5B RNA polymerase inhibitor This undergoes intracellular metabolism to form uridine analogue triphosphate Inhibition of viral multiplication occurs by incorporating into HCV RNA and acts as a chain terminator Velpatasvir HCV NS5A protein inhibitor, it blocks the protein activity and inhibits viral multiplication. Pharmacokinetic: 12 weeks Absorption: The Velasof tablet was quickly absorbed after oral administration. The peak plasma concentration of both component in Velasof and active metabolite of Velasof (GS-461203) occurs within 1 hour, 3 hours, and 3 hours respectively Distribution: Food does not interfere with Velasof action Sofosbuvir, Plasma protein binding: 61-65% Velpatasvir, plasma protein bound: >99.5% The active metabolite of the tablet Velasof has poor protein binding property. Metabolism: Sofosbuvir is metabolized in liver, changed to active analogue triphosphate GS-461203 Elimination: 80% metabolite eliminated: urine; 14% of metabolites: faeces; 2.5%: exhaled air The terminal half life of Velasof tablet is 15 hours

Indication of Velasof - 12 weeks

Velasof is mainly indicated for the patients who are suffered with chronic hepatitis C viral infection associated genotype I, II, III, IV, V or VI infection. Generally Velasof tablets are taken for 12 weeks, it may effective in patients. Types of hepatitis Without cirrhosis or with compensated cirrhosis With decompensated cirrhosis with use of ribavirin

Dose & Dosage's of Velasof - 12 weeks

Velasof dosage and administration – 12 weeks Velasof is recommended for adults. The safety and efficacy of the drug has not been established for children. Chronic hepatitis C virus (HCV) infection genotypes I, II, III, IV, V or VI One tablet to be taken as a single dose Velasof should be taken with or without food If patient without cirrhosis or compensated cirrhosis (child Pugh A): Take Velasof tablet for 12 weeks If patient with decompensated cirrhosis (child Pugh B or C) should take as combination of Velasof and ribavirin for 12 weeks The dose of ribavirin recommended on the basis of weight of patient; <75 kg: 1000mg/day twice daily ≥75 kg: 1200mg/day twice daily The dosage of ribavirin should be decreased on the basis of hemoglobin and creatine clearance levels. Missed dose: If patient missed the dose of Velasof tablet, should be skipped and follow the next dose schedule Do not take double dose

Side Effects of Velasof - 12 weeks

Velasof side effects: 12 weeks Patients Without cirrhosis Headache, fatigue, shortness of breath, chest pain Patients With decompensated cirrhosis Fatigue, anemia, decreased hemoglobulin levels, nausea, headache, insomnia 1-10% of patients attain; Patients Without cirrhosis; Lipase increase, rash, depression, increased creatine kinase, insomnia, asthenia Patients With decompensated cirrhosis; Diarrhea, hemoglobin levels get depleted, rash, increased creatine kinase Common side effects: Headache, unusual tiredness, chest pain, swelling of peripheral organs, skin rashes, breathing trouble Post marketing reports: angioedema

Contraindication of Velasof - 12 weeks

Velasof while combining with ribavirin for advanced cirrhosis, in this condition it is contraindicated to the pregnant women and women who become pregnant, ribavirin cause harm to the fetal

Drug Interaction of Velasof - 12 weeks

While taking Velasof for 12 weeks, some of the drugs should not taken in combination; Ant acids: aluminium hydroxide, magnesium hydroxide, calcium carbonate H2 receptor antagonist: famotidine, ranitidine, Cimetidine Proton pump inhibitors: Omeprazole, esomeprozole, pantoprazole, lansoprazole Anti-arrhythmic: amiodarone, digoxin Anti-cancer: topotecan Anti-mycobacterials: rifabutin, rifampin, rifapentine HIV antiretroviral: efavirenz, tenofovir, tipranavir ritonavir Herbal supplements: st. Johns wort Anti convulsants: carbamazepine, phenytoin, Phenobarbital, oxcarbazepine HMG CoA reductase inhibitors: rosuvastatin, Atorvastatin

Precaution of Velasof - 12 weeks

Risk of HBV reactivation in patient co infected with HCV and HBV Co administration of amiodarone with Velasof causes bradycardia; caution should be taking while combining with amiodarone Caution with use in Liver and kidney impairment patients

Usage & Safety profile of Velasof - 12 weeks Pregnancy & Lactation

Velasof with ribavirin is not safe to use in pregnancy condition, it may leads to fetal death Breast feeding is not recommended

Storage of Velasof - 12 weeks

Velasof should be stored at room temperature. Velasof container should be keep away from moisture, heat, and light